Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily pill shield transplant patients from a common virus?

NCT ID NCT07706166

Prevention Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Aug 27, 2026 · Updated 3 times

Summary

This study investigates whether the drug letermovir can prevent cytomegalovirus (CMV) infection in adults who have received a kidney or liver transplant and have been previously exposed to CMV. Participants take one letermovir tablet daily for 84 days after transplant. The goal is to see if this approach reduces the rate of CMV breakthrough or treatment withdrawal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
letermovir
What this could lead to
If effective, letermovir could become a standard preventive treatment for CMV in moderate-risk transplant recipients, reducing infection-related complications.
What could go wrong
This is a single-arm Phase 4 study with no placebo comparison, so results may be less definitive. The drug may cause side effects or fail to prevent CMV in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+) * Adults who received a kidney transplant, liver transplant, or any combination thereof Exclusion Criteria: * Known contraindication to letermovir or its excipients * Current participation in another CMV related study * Unwilling or unable to participate in the study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant Liver transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Wisconsin - Madison

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.